Matrix metalloproteinase-2 as a target for head and neck cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 2, 2013, Pages 203-216

  Chien, Ming Hsien ^a,b   Lin, Chiao Wen ^c,d   Cheng, Chao Wen ^a   Wen, Yu Ching ^a,b   Yang, Shun Fa ^c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Head and neck cancer; MMP 2; Molecular target; Signaling networks

Indexed keywords

2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; AE 941; ALPHA INTERFERON; BATIMASTAT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXYCYCLINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GELATINASE A; GEMCITABINE; INCYCLINIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE PROTEIN; OSTHOLE; PACLITAXEL; PEPTIDOMIMETIC AGENT; PRINOMASTAT; REBIMASTAT; SILIBININ; SOLIMASTAT; TANOMASTAT; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTHRALGIA; BLOOD TOXICITY; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL MIGRATION; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL TUMOR; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LARYNX SQUAMOUS CELL CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MACULOPAPULAR RASH; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUTH CANCER; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; MYALGIA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIODONTITIS; PHOTOSENSITIVITY; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS;

EID: 84872240151     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.740012     Document Type: Review

References (126)

1. Myers JN, Greenberg JS, Mo V, et al. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer 2001;92:3030-6 (Pubitemid 33136197)
2. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997;80:1529-37 (Pubitemid 27444024)
3. Liotta LA. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1-7 (Pubitemid 16189019)
4. Wu CY, Wu MS, Chen YJ, et al. Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 2007;43:799-808
5. Yu C, Zhou Y, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004;64:7622-8 (Pubitemid 39372109)
6. Arenas-Huertero FJ, Herrera-Goepfert R Delgado-Chavez R, et al. Matrix metalloproteinases expressed in squamous cell carcinoma of the oral cavity: Correlation with clinicopathologic features and neo-adjuvant chemotherapy response. J Exp Clin Cancer Res 1999;18:279-84
7. O-Charoenrat P, Rhys-Evans PH Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:813-20 (Pubitemid 32619361)
8. Patel BP, Shah PM, Rawal UM, et al. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J Surg Oncol 2005;90:81-8 (Pubitemid 40594106)
9. Zhou CX, Gao Y, Johnson NW, et al. Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust Dent J 2010;55:385-9
10. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: A mini-review. Med Sci Monit 2009;15:RA32-40
11. Kandasamy AD, Chow AK, Ali MA et al. Matrix metalloproteinase-2 and myocardial oxidative stress injury: Beyond the matrix. Cardiovasc Res 2010;85:413-23
12. Salo T, Liotta LA, Tryggvason K. Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. J Biol Chem 1983;258:3058-63 (Pubitemid 13130228)
13. Hoyhtya M, Turpeenniemi-Hujanen T Stetler-Stevenson W, et al. Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin. FEBS Lett 1988;233:109-13
14. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74 (Pubitemid 37328786)
15. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4
16. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17:6330-8 (Pubitemid 27451177)
17. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999;274:29130-7
18. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: Role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001;276:7549-58
19. Lin SC, Lo SS, Liu CJ, et al. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 2004;33:405-9
20. Woessner JF Jr. Role of matrix proteases in processing enamel proteins. Connect Tissue Res 1998;39:69-73; discussion 141-149
21. Okamoto T, Akaike T, Sawa T, et al. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001;276:29596-602
22. Morgunova E, Tuuttila A, Bergmann U et al. Structure of human pro-matrix metalloproteinase-2: Activation mechanism revealed. Science 1999;284:1667-70 (Pubitemid 29291376)
23. Rauch BH, Bretschneider E, Braun M et al. Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: Role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ Res 2002;90:1122-7 (Pubitemid 34627912)
24. Zucker S, Conner C, DiMassmo BI et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem 1995;270:23730-8
25. Cao J, Sato H, Takino T, et al. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995;270:801-5
26. Lafleur MA, Tester AM, Thompson EW. Selective involvement of TIMP-2 in the second activational cleavage of pro-MMP-2: Refinement of the pro-MMP-2 activation mechanism. FEBS Lett 2003;553:457-63 (Pubitemid 37315649)
27. Helvering LM, Adrian MD, Geiser AG et al. Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus. Biol Reprod 2005;72:830-41 (Pubitemid 40404257)
28. Liang Q, Xiong H, Gao G, et al. Inhibition of basigin expression in glioblastoma cell line via antisense RNA reduces tumor cell invasion and angiogenesis. Cancer Biol Ther 2005;4:759-62 (Pubitemid 41351176)
29. Rosenthal EL, Shreenivas S, Peters GE et al. Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 2003;113:1406-10 (Pubitemid 36944687)
30. Yang X, Zhang P, Ma Q, et al. EMMPRIN contributes to the in vitro invasion of human salivary adenoid cystic carcinoma cells. Oncol Rep 2012;27:1123-7
31. Vigneswaran N, Beckers S, Waigel S et al. Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol 2006;80:147-59
32. Lescaille G, Menashi S Cavelier-Balloy B, et al. EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. BMC Cancer 2012;12:115
33. Dang D, Atakilit A, Ramos DM. EMMPRIN modulates migration and deposition of TN-C in oral squamous carcinoma. Anticancer Res 2008;28:2049-54
34. Yang X, Zhang P, Ma Q, et al. EMMPRIN silencing inhibits proliferation and perineural invasion of human salivary adenoid cystic carcinoma cells in vitro and in vivo. Cancer Biol Ther 2012;13:85-91
35. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010;141:52-67
36. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271-90
37. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287-97
38. Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010;1803:39-54
39. Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: Contrasting overlapping and compensatory functions. Biochim Biophys Acta 2010;1803:103-20
40. Baluk P, Raymond WW, Ator E, et al. Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. Am J Physiol Lung Cell Mol Physiol 2004;287:L307-17 (Pubitemid 38943913)
41. Hotary K, Li XY, Allen E, et al. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 2006;20:2673-86 (Pubitemid 44498378)
42. Sabeh F, Li XY, Saunders TL, et al. Secreted versus membrane-anchored collagenases: Relative roles in fibroblast-dependent collagenolysis and invasion. J Biol Chem 2009;284:23001-11
43. Giannelli G, Falk-Marzillier J Schiraldi O, et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8 (Pubitemid 27446075)
44. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:436-44
45. Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011;23:951-62
46. Levi E, Fridman R, Miao HQ, et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996;93:7069-74 (Pubitemid 26243503)
47. Hatfield KJ, Reikvam H, Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem 2010;17:4448-61
48. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69 (Pubitemid 40720240)
49. McQuibban GA, Gong JH, Tam EM et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-6 (Pubitemid 30650734)
50. Hofmann UB, Houben R, Brocker EB et al. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005;87:307-14 (Pubitemid 40387609)
51. Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: Role of the complexes in leukocyte migration and cancer progression. Blood 2006;108:1441-50 (Pubitemid 44316107)
52. Hahn-Dantona E, Ruiz JF, Bornstein P et al. The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J Biol Chem 2001;276:15498-503
53. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001;276:8403-8
54. Brooks PC, Stromblad S, Sanders LC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996;85:683-93 (Pubitemid 26181048)
55. Menashi S, Dehem M, Souliac I, et al. Density-dependent regulation of cell-surface association of matrix metalloproteinase-2 (MMP-2) in breast-carcinoma cells. Int J Cancer 1998;75:259-65 (Pubitemid 28100068)
56. Hofmann UB, Westphal JR Van Kraats AA, et al. Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer 2000;87:12-19
57. Silletti S, Kessler T, Goldberg J, et al. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001;98:119-24 (Pubitemid 32095873)
58. Stefanidakis M, Bjorklund M, Ihanus E et al. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. J Biol Chem 2003;278:34674-84 (Pubitemid 37553317)
59. Levkau B, Kenagy RD, Karsan A, et al. Activation of metalloproteinases and their association with integrins: An auxiliary apoptotic pathway in human endothelial cells. Cell Death Differ 2002;9:1360-7 (Pubitemid 36097706)
60. Rupp PA, Visconti RP, Czirok A, et al. Matrix metalloproteinase 2-integrin alpha (v)beta3 binding is required for mesenchymal cell invasive activity but not epithelial locomotion: A computational time-lapse study. Mol Biol Cell 2008;19:5529-40
61. Chetty C, Lakka SS, Bhoopathi P, et al. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 2010;127:1081-95
62. Agnantis NJ, Goussia AC, Batistatou A et al. Tumor markers in cancer patients. an update of their prognostic significance. Part II. In Vivo 2004;18:481-8 (Pubitemid 39199996)
63. Ogasawara S, Yano H, Momosaki S et al. Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncol Rep 2005;13:1043-8
64. Talvensaari-Mattila A, Paakko P Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003;89:1270-5 (Pubitemid 37363416)
65. Di Carlo A, Terracciano D, Mariano A et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol 2005;26:1363-8
66. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope 2004;114:2243-8 (Pubitemid 39602498)
67. Katayama A, Bandoh N, Kishibe K et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004;10:634-40 (Pubitemid 38174003)
68. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500 (Pubitemid 38610250)
69. Bogusiewicz M, Stryjecka-Zimmer M Szymanski M, et al. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg 2003;128:132-6 (Pubitemid 36246131)
70. Yorioka CW, Coletta RD, Alves F, et al. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol 2002;20:189-94
71. Shimada T, Nakamura H, Yamashita K et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. Clin Exp Metastasis 2000;18:179-88 (Pubitemid 32165252)
72. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5 (Pubitemid 24216953)
73. Okada A, Bellocq JP, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 1995;92:2730-4
74. Birkedal-Hansen B, Pavelic ZP Gluckman JL, et al. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues. Oral Dis 2000;6:376-82
75. Eeckhout Y, Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 1977;166:21-31 (Pubitemid 8127122)
76. Keski-Oja J, Lohi J, Tuuttila A, et al. Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res 1992;202:471-6
77. Schmidt M, Grunsfelder P. Urokinase-type plasminogen activator expression and proliferation stimulation in head and neck squamous cell carcinoma in vitro and in situ. Arch Otolaryngol Head Neck Surg 2001;127:679-82 (Pubitemid 32705874)
78. Coussens LM, Fingleton B Matrisian LM. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002;295:2387-92 (Pubitemid 34270240)
79. Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009;1:382-93
80. Schafer JM, Peters DE, Morley T, et al. Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin. PLoS One 2011;6:e20532
81. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol 2007;26:587-96 (Pubitemid 350180394)
82. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 2000;19:623-9
83. O-Charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 2006;42:257-67 (Pubitemid 43246757)
84. Chaudhary AK, Pandya S, Mehrotra R et al. Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers 2011;16:577-86
85. Vairaktaris E, Yapijakis C Yiannopoulos A, et al. Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 2007;17:963-8
86. Nelson AR, Fingleton B Rothenberg ML, et al. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49 (Pubitemid 30123793)
87. Macaulay VM, O'Byrne KJ Saunders MP, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999;5:513-20 (Pubitemid 29131959)
88. Beattie GJ, Smyth JF. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998;4:1899-902 (Pubitemid 28369173)
89. Sparano JA, Bernardo P, Stephenson P et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004;22:4683-90
90. Tierney GM, Griffin NR, Stuart RC et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 1999;35:563-8 (Pubitemid 29192963)
91. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 1999;878:236-70 (Pubitemid 29353575)
92. Bissett D, O'Byrne KJ, von Pawel J et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005;23:842-9 (Pubitemid 46224184)
93. Rowinsky EK, Humphrey R Hammond LA, et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000;18:178-86 (Pubitemid 30036351)
94. Heath EI, O'Reilly S, Humphrey R et al. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2001;48:269-74 (Pubitemid 32835350)
95. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178-93 (Pubitemid 32166488)
96. Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999;43(Suppl):S61-8 (Pubitemid 29244635)
97. Rizvi NA, Humphrey JS, Ness EA, et al. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004;10:1963-70 (Pubitemid 38375554)
98. Lara PN Jr, Stadler WM, Longmate J et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006;12:1556-63
99. Miller KD, Saphner TJ Waterhouse DM, et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 2004;10:1971-5 (Pubitemid 38375555)
100. Leighl NB, Paz-Ares L, Douillard JY et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: national Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005;23:2831-9 (Pubitemid 46179474)
101. Levitt NC, Eskens FA, O'Byrne KJ et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-22 (Pubitemid 32994825)
102. Eatock M, Cassidy J, Johnson J, et al. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 2005;55:39-46 (Pubitemid 40064494)
103. Chang HR, Chen PN, Yang SF, et al. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel. Mol Carcinog 2011;50:811-23
104. Bousserouel S, Bour G, Kauntz H, et al. Silibinin inhibits tumor growth in a murine orthotopic hepatocarcinoma model and activates the TRAIL apoptotic signaling pathway. Anticancer Res 2012;32:2455-62
105. Yousefi M, Ghaffari SH, Soltani BM et al. Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-kappaB expressions may play an important role in silibinin-induced response. Neurochem Res 2012;37:2053-63
106. Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010;70:848-55
107. Yang LL, Wang MC, Chen LG, et al. Cytotoxic activity of coumarins from the fruits of Cnidium monnieri on leukemia cell lines. Planta Med 2003;69:1091-5
108. Kao SJ, Su JL, Chen CK, et al. Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-kappaB-mediated matrix metalloproteinase-9 expression. Toxicol Appl Pharmacol 2012;261:105-15
109. Yang D, Gu T, Wang T, et al. Effects of osthole on migration and invasion in breast cancer cells. Biosci Biotechnol Biochem 2010;74:1430-4
110. Dredge K. AE-941 (AEterna). Curr Opin Investig Drugs 2004;5:668-77
111. Dupont E, Falardeau P, Mousa SA, et al. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 2002;19:145-53 (Pubitemid 34264084)
112. Batist G, Patenaude F, Champagne P et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: Report of a phase II trial with two dose levels. Ann Oncol 2002;13:1259-63 (Pubitemid 34960135)
113. Latreille J, Batist G, Laberge F, et al. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003;4:231-6 (Pubitemid 36758172)
114. Lokeshwar BL, Selzer MG, Zhu BQ et al. Inhibition of cell proliferation invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002;98:297-309 (Pubitemid 34150817)
115. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study. J Clin Oncol 2002;20:153-9 (Pubitemid 34032606)
116. Chu QS, Forouzesh B, Syed S, et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 2007;25:359-67 (Pubitemid 46944843)
117. Teronen O, Heikkila P, Konttinen YT et al. MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 1999;878:453-65 (Pubitemid 29353588)
118. Farina AR, Tacconelli A, Teti A, et al. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. Cancer Res 1998;58:2957-60 (Pubitemid 28335069)
119. Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck 2006;28:639-48 (Pubitemid 44025114)
120. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39 (Pubitemid 43292566)
121. Sela-Passwell N, Rosenblum G Shoham T, et al. Structural and functional bases for allosteric control of MMP activities: Can it pave the path for selective inhibition? Biochim Biophys Acta 2010;1803:29-38
122. Bjorklund M, Heikkila P, Koivunen E. Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion. J Biol Chem 2004;279:29589-97 (Pubitemid 38915841)
123. Dufour A, Zucker S, Sampson NS, et al. Role of matrix metalloproteinase-9 dimers in cell migration: Design of inhibitory peptides. J Biol Chem 2010;285:35944-56
124. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004;6:507-14 (Pubitemid 38786593)
125. Song X, Wang X, Zhuo W, et al. The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 processing and tumor angiogenesis. J Biol Chem 2010;285:40039-49
126. Stellas D, El Hamidieh A, Patsavoudi E. Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 2010;11:51